Literature DB >> 32191521

The "Abortion Pill" Misoprostol in Brazil: Women's Empowerment in a Conservative and Repressive Political Environment.

Ilana Löwy1, Marilena Cordeiro Dias Villela Corrêa1.   

Abstract

In the aftermath of the introduction of severe restrictions on abortion in several US states, some activists have argued that providing widespread access to an abortive drug, misoprostol, will transform an induced abortion into a fully private act and therefore will empower women. In Brazil, where abortion is criminalized, the majority of women who wish to terminate an unwanted pregnancy already use the illegal, but easily accessible, misoprostol. We examine the history of misoprostol as an abortifacient in Brazil from the late 1980s until today and the professional debates on the teratogenicity of this drug. The effects of a given pharmaceutical compound, we argue, are always articulated, elicited, and informed within dense networks of sociocultural, economic, legal, and political settings. In a conservative and repressive environment, the use of misoprostol for self-induced abortions, even when supported by formal or informal solidarity networks, is far from being a satisfactory solution to the curbing of women's reproductive rights.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32191521      PMCID: PMC7144453          DOI: 10.2105/AJPH.2019.305562

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  11 in total

Review 1.  Bioethics, raw and cooked: extraordinary conflict and everyday practice.

Authors:  Charles L Bosk
Journal:  J Health Soc Behav       Date:  2010

2.  Misoprostol and legal medical abortion.

Authors: 
Journal:  Lancet       Date:  1991-11-16       Impact factor: 79.321

3.  Brazil: misuse of misoprostol as an abortifacient may induce malformations.

Authors:  P S Schönhöfar
Journal:  Lancet       Date:  1991-06-22       Impact factor: 79.321

Review 4.  Prenatal exposure to misoprostol and congenital anomalies: systematic review and meta-analysis.

Authors:  Tatiane da Silva Dal Pizzol; Flávia Pozzobon Knop; Sotero Serrate Mengue
Journal:  Reprod Toxicol       Date:  2006-06-05       Impact factor: 3.143

5.  "Proof" of human teratogenicity.

Authors:  T H Shepard
Journal:  Teratology       Date:  1994-08

6.  Taking drugs during pregnancy. How safe are the unsafe?

Authors:  G Koren; L Schuler
Journal:  Can Fam Physician       Date:  2001-05       Impact factor: 3.275

Review 7.  Commercial availability of misoprostol and induced abortion in Brazil.

Authors:  S H Costa
Journal:  Int J Gynaecol Obstet       Date:  1998-12       Impact factor: 3.561

8.  Misoprostol alone for early abortion: an evaluation of seven potential regimens.

Authors:  Kelly Blanchard; Tara Shochet; Kurus Coyaji; Nguyen Thi Nhu Ngoc; Beverly Winikoff
Journal:  Contraception       Date:  2005-08       Impact factor: 3.375

9.  Congenital abnormalities in Brazilian children associated with misoprostol misuse in first trimester of pregnancy.

Authors:  C H Gonzalez; M J Marques-Dias; C A Kim; S M Sugayama; J A Da Paz; S M Huson; L B Holmes
Journal:  Lancet       Date:  1998-05-30       Impact factor: 79.321

10.  Misoprostol: the experience of women in Fortaleza, Brazil.

Authors:  H L Coêlho; A C Teixeira; M de F Cruz; S L Gonzaga; P S Arrais; L Luchini; C La Vecchia; G Tognoni
Journal:  Contraception       Date:  1994-02       Impact factor: 3.375

View more
  3 in total

1.  A Stalled Revolution? Misoprostol and the Pharmaceuticalization of Reproductive Health in Francophone Africa.

Authors:  Siri Suh
Journal:  Front Sociol       Date:  2021-04-12

2.  The Duogynon controversy and ignorance production in post-thalidomide West Germany.

Authors:  Birgit Nemec; Jesse Olszynko-Gryn
Journal:  Reprod Biomed Soc Online       Date:  2021-10-19

3.  Rethinking ignorance production in the field of reproductive biomedicine: An introduction.

Authors:  Sezin Topçu; Irène Maffi
Journal:  Reprod Biomed Soc Online       Date:  2021-12-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.